SMS Pharmaceuticals · NSE: SMSPHARMA · BSE: 532815
Q3 FY22 results · Oct–Dec 2021
SMS Pharmaceuticals reported revenue from operations of ₹121.25 crore (down 18.5% from Q3 FY21) and net profit of ₹10.27 crore (down 52.0% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 121.25 | 148.87 | −18.5% | 174.70 | −30.6% |
| Other income | 2.13 | 0.86 | +148.9% | 1.36 | +57.2% |
| Total income | 123.38 | 149.72 | −17.6% | 176.06 | −29.9% |
| Profit before tax | 16.33 | 26.75 | −39.0% | 35.24 | −53.7% |
| Net profit for the period | 10.27 | 21.39 | −52.0% | 23.03 | −55.4% |
| EPS, basic (₹) | 1.07 | 2.53 | −57.7% | 2.72 | −60.7% |
| Net margin (%) | 8.5 | 14.4 | 13.2 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 121.25 | 148.87 | −18.5% | 174.70 | −30.6% |
| Other income | 2.13 | 0.86 | +148.9% | 1.36 | +57.2% |
| Total income | 123.38 | 149.72 | −17.6% | 176.06 | −29.9% |
| Profit before tax | 16.56 | 26.75 | −38.1% | 35.50 | −53.3% |
| Net profit for the period | 10.51 | 18.32 | −42.7% | 25.27 | −58.4% |
| EPS, basic (₹) | 1.24 | 2.16 | −42.6% | 2.99 | −58.5% |
| Net margin (%) | 8.7 | 12.3 | 14.5 |
Consolidated
- Filed with BSE
- 09 Feb 2022, 16:42 IST
- Board meeting
- 09 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Feb 2022, 16:42 IST
- Board meeting
- 09 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE